Apellis Pharmaceuticals Inc. (APLS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Apellis Pharmaceuticals I... (APLS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

27.69

-0.90 (-3.15%)

At close: Jan 14, 2025, 3:59 PM

28.00

1.12%

After-hours Jan 14, 2025, 06:38 PM EST

undefined% (undefined)

Bid	27
Market Cap	3.44B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.03
PE Ratio (ttm)	-13.64
Forward PE	n/a
Analyst	Buy

Ask	33
Volume	1,198,797
Avg. Volume (20D)	3,141,677
Open	29.25
Previous Close	28.59
Day's Range	27.68 - 29.25
52-Week Range	24.34 - 71.90
Beta	undefined

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 9, 2017

Employees 702

Stock Exchange NASDAQ

Ticker Symbol APLS

Website https://www.apellis.com

Analyst Forecast

According to 18 analyst ratings, the average rating for APLS stock is "Buy." The 12-month stock price forecast is $41, which is an increase of 48.07% from the latest price.

Buy 55.56%

Hold 44.44%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Apellis Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $191.93M, reflecting a 31.12% YoY growth and earnings per share of -0.37, making a -49.32% decrease YoY.

Why Price Moved

1 day ago · Source New

+4.19%

Apellis Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

2 months ago · Source

-1.68%

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

News

1 month ago · zacks.com

Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?

2 months ago · zacks.com

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.

2 months ago · fool.com

Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

Sales of the company's top commercialized product didn't meet expectations.

2 months ago · seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Meredith Kaya - Senior Vice President of Investor Relations and Strategic...

2 months ago · zacks.com

Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compa...

2 months ago · zacks.com

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago.

2 months ago · zacks.com

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · fool.com

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.

3 months ago · benzinga.com

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. APLS and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of two thera...